Ceva Santé Animale and ProBioGen have announced the signature of a multi-product license agreement for the use of ProBioGen’s AGE1.CR avian cell line in the industrial production of viral animal vaccines.

In a preceding pilot study Ceva evaluated the technology, which allows cells to grow rapidly and in high cell densities in ProBioGen’s proprietary chemically defined medium. Master cell banking for one viral vaccine strain has been completed and further development projects are underway.